---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: OP-1250-003"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: OP-1250-003. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 58 evidence topics quoted from 16 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence/op-1250-003"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: OP-1250-003

<a id="heading-3.1.3"></a>

## 3.1.3 OP-1250-003

<a id="heading-3.1.3.1"></a>

### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

#### Dose escalation and dose expansion objectives

> “determine the RP2D (Recommended Phase 2 Dose) for each treatment group”
> “provide an exploratory estimate of anti-tumor activity of the combinations”

Source: [ClinicalTrials.gov NCT05508906](https://clinicaltrials.gov/study/NCT05508906)

<a id="topic-3.1.3.1-2"></a>

#### Original objective for the ribociclib and alpelisib groups

> “To evaluate the safety, pharmacokinetics, and antitumor activity of daily, oral administration of OP-1250 plus ribociclib or alpelisib in patients with advanced or metastatic HR+/HER2− breast cancer”

Source: [Borges et al. (2023a)](https://olema.com/wp-content/uploads/2023/06/Olema_ASCO_OP1250-003-TIP_Poster_6-4-23.pdf)

<a id="topic-3.1.3.1-3"></a>

#### Atirmociclib group objective

> “The companies will evaluate in a Phase 1b/2 study the safety and combinability of palazestrant plus atirmociclib, Pfizer’s investigational, highly selective-CDK4 inhibitor, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) metastatic breast cancer.”

Source: [Olema Oncology Pfizer atirmociclib agreement announcement (2025)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-new-clinical-trial-agreement-pfizer)

<a id="heading-3.1.3.2"></a>

### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

#### Registry dates and planned enrollment

| Item | Value |
| --- | --- |
| Study start (actual) | “2022-08-31” |
| Primary completion (estimated) | “2027-12-31” |
| Study completion (estimated) | “2028-01-31” |
| Enrollment (estimated) | “190” |

Source: [ClinicalTrials.gov NCT05508906](https://clinicaltrials.gov/study/NCT05508906)

<a id="topic-3.1.3.2-2"></a>

#### Planned study sites

> “Enrollment is ongoing and expected at approximately 20 sites in the United States and Australia.”

Source: [Borges et al. (2023a)](https://olema.com/wp-content/uploads/2023/06/Olema_ASCO_OP1250-003-TIP_Poster_6-4-23.pdf)

<a id="topic-3.1.3.2-3"></a>

#### Ribociclib group: most recent data cutoff and presentation

> “78 patients were enrolled in the dose-expansion and dose-escalation cohorts as of July 8, 2025.”
> “Poster presented at: European Society for Medical Oncology Congress; October 17-21, 2025; Berlin, Germany.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.2-4"></a>

#### Everolimus group initiation

> “In the third quarter of 2024, we initiated evaluation of palazestrant in combination with everolimus in a Phase 1b/2 clinical study.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="topic-3.1.3.2-5"></a>

#### Atirmociclib group initiation and enrollment

> “Initiated the Phase 1b/2 study evaluating palazestrant in combination with atirmociclib in estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) metastatic breast cancer in collaboration with Pfizer.”

Source: [Olema Oncology fourth quarter and full year 2025 results announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-fourth-quarter-and-full-year-2025)

<a id="topic-3.1.3.2-6"></a>

#### Atirmociclib group enrollment completed

> “Completed enrollment in the Phase 1b/2 study of palazestrant in combination with atirmociclib in ER+/HER2- MBC.”

Source: [Olema Oncology second quarter 2026 results announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-second-quarter-2026-financial-and)

<a id="heading-3.1.3.3"></a>

### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

#### Phase 1b open-label design with four treatment groups

> “This is a Phase 1b open-label, 2-part study in 4 treatment groups.”
> “Treatment Group 4: Palazestrant in combination with atirmociclib”

Source: [ClinicalTrials.gov NCT05508906](https://clinicaltrials.gov/study/NCT05508906)

<a id="topic-3.1.3.3-2"></a>

#### Dose escalation followed by dose expansion

> “The OP-1250-003 study comprises a dose-escalation phase, followed by a dose-expansion phase. The study investigates palazestrant in combination with ribociclib, alpelisib, or everolimus.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.3-3"></a>

#### Dose-escalation method

> “3 + 3 design”

Source: [Borges et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-003_12-5-23.pdf)

<a id="topic-3.1.3.3-4"></a>

#### Alternate dose level in the ribociclib group

> “An additional group of palazestrant at an alternate dose level in combination with ribociclib (Treatment Group 1b) will be explored to optimize the RP2D of palazestrant.”

Source: [ClinicalTrials.gov NCT05508906](https://clinicaltrials.gov/study/NCT05508906)

<a id="topic-3.1.3.3-5"></a>

#### Expansion of the ribociclib group

> “The amendment adds approximately 30 patients to be enrolled in the cohort expansion phase of the palazestrant clinical study in combination with ribociclib.”

Source: [Olema Oncology Novartis collaboration expansion announcement (2023)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-expansion-collaboration-agreement)

<a id="heading-3.1.3.4"></a>

### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

#### Ribociclib group: key eligibility criteria

> “Women or men with ER+, HER2− advanced or metastatic breast cancer.”
> “Up to 2 prior endocrine therapies ± a CDK4/6i for locally advanced or metastatic disease; up to 1 prior line of chemotherapy for advanced or metastatic breast cancer was allowed.”
> “Evaluable disease (measurable by RECIST v1.1 or bone only).”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.4-2"></a>

#### Cardiac screening criteria

> “Screening QTcF <450 ms, resting heart rate 50-90 beats/min”

Source: [Borges et al. (2024b)](https://ir.olema.com/static-files/dfb83ebb-df49-47a3-a585-ec416cc48954)

<a id="topic-3.1.3.4-3"></a>

#### Prior therapy limits by treatment group in the current registry record

> “Has received no more than 1 prior hormonal regimen (Treatment Group 1).”
> “Prior hormonal regimens in combination with CDK4/6 inhibitors are allowed in all treatment groups.”
> “For subjects in Treatment Group 4, no prior chemotherapy for metastatic breast cancer is allowed.”
> “Have received prior treatment with approved or investigational PI3K inhibitor (Treatment Group 2) or mTOR inhibitor (Treatment Group 3).”

Source: [ClinicalTrials.gov NCT05508906](https://clinicaltrials.gov/study/NCT05508906)

<a id="topic-3.1.3.4-4"></a>

#### Alpelisib group and central nervous system criteria

> “Presence of PIK3CA mutation”
> “No prior treatment with a PI3K inhibitor (OP-1250 plus alpelisib group)”
> “Patients with stable or treated brain metastases are eligible”

Source: [Borges et al. (2023a)](https://olema.com/wp-content/uploads/2023/06/Olema_ASCO_OP1250-003-TIP_Poster_6-4-23.pdf)

<a id="heading-3.1.3.5"></a>

### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

#### Ribociclib group: dose escalation regimen

> “palazestrant at 30, 60, and 120 mg once daily plus ribociclib 600 mg once daily on days 1–21 of each 28-day treatment cycle”

Source: [Borges et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-003_12-5-23.pdf)

<a id="topic-3.1.3.5-2"></a>

#### Ribociclib group: doses in the most recent analysis

> “Here we present the data for 72 patients: 56 patients received 120 mg QD palazestrant and 16 patients received 90 mg QD palazestrant, all with 600 mg of ribociclib.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.5-3"></a>

#### Alpelisib, everolimus, and atirmociclib group regimens

> “with 300 mg or 250 mg of alpelisib administered PO daily (Treatment Group 2) or with everolimus 10 mg administered PO daily (Treatment Group 3)”
> “Part 1, for Treatment Group 4, will evaluate the safety and pharmacokinetics of OP-1250 at 60 mg or 90 mg doses administered orally (PO) QD in combination with atirmociclib 300 mg PO twice a day (BID).”

Source: [ClinicalTrials.gov NCT05508906](https://clinicaltrials.gov/study/NCT05508906)

<a id="heading-3.1.3.6"></a>

### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

#### 3.1.3.6.1 Rationale for Using Dose-limiting Toxicities as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

##### Ribociclib group: primary and secondary endpoints by study part

| Part | Primary endpoints | Secondary endpoints |
| --- | --- | --- |
| Dose escalation | “DLTs, MTD, and/or RP2D of palazestrant when administered in combination with ribociclib, incidence and severity of adverse events, PK” | “ORR (CR + PR), CBR (CR + PR + SD ≥24 weeks), DOR” |
| Dose expansion | “Incidence and severity of adverse events, PK” | “ORR (CR + PR), CBR (CR + PR + SD ≥24 weeks), DOR, time to progression, PFS” |

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.6.1-2"></a>

##### Dose-limiting toxicity assessment window

> “The incidence of DLTs will be assessed in the Dose Escalation part (Part 1) of the study.”
> “The first 28 days of treatment”

Source: [ClinicalTrials.gov NCT05508906](https://clinicaltrials.gov/study/NCT05508906)

<a id="topic-3.1.3.6.1-3"></a>

##### Dose-limiting toxicity observation period in the ribociclib group

> “the DLT observation period was at least 4 weeks”

Source: [Borges et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-003_12-5-23.pdf)

<a id="topic-3.1.3.6.1-4"></a>

##### Response assessment

> “as assessed by the investigator using RECIST v1.1.”

Source: [ClinicalTrials.gov NCT05508906](https://clinicaltrials.gov/study/NCT05508906)

<a id="heading-3.1.3.7"></a>

### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

#### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

##### Planned ribociclib group size after the 2023 amendment

> “to increase the size of the ongoing Phase 1/2 clinical study testing palazestrant in combination with ribociclib to approximately 60 patients.”

Source: [Olema Oncology Novartis collaboration expansion announcement (2023)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-expansion-collaboration-agreement)

<a id="topic-3.1.3.7.1-2"></a>

##### Ribociclib group: enrolled and analyzed participants, July 2025 data cutoff

> “78 patients were enrolled in the dose-expansion and dose-escalation cohorts as of July 8, 2025.”
> “Here we present the data for 72 patients: 56 patients received 120 mg QD palazestrant and 16 patients received 90 mg QD palazestrant, all with 600 mg of ribociclib.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.7.1-3"></a>

##### Ribociclib group: participants by cohort, July 2025 data cutoff

| Cohort | Participants |
| --- | --- |
| Dose escalation, palazestrant 30 mg | “30 mg (n=3)” |
| Dose escalation, palazestrant 60 mg | “60 mg (n=3)” |
| Dose escalation, palazestrant 120 mg | “120 mg (n=3)” |
| Dose expansion, palazestrant 90 mg | “90 mg (n=16)” |
| Dose expansion, palazestrant 120 mg | “120 mg (n=53)” |

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.7.1-4"></a>

##### Ribociclib group: March 2024 interim analysis population

> “60 patients were enrolled as of March 13, 2024; 50 patients who had 4 weeks or more of follow-up were included in this analysis.”

Source: [Borges et al. (2024a)](https://olema.com/wp-content/uploads/2024/05/Olema_Final_ESMO-Breast-2024_OP-1250-003_5-15-24.pdf)

<a id="topic-3.1.3.7.1-5"></a>

##### Ribociclib group: September 2024 interim analysis population

> “62 patients were enrolled as of September 25, 2024.”

Source: [Borges et al. (2024b)](https://ir.olema.com/static-files/dfb83ebb-df49-47a3-a585-ec416cc48954)

<a id="heading-3.1.3.7.2"></a>

#### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

##### Response-evaluable population

> “34% (15/44) objective response rate (ORR) among response-evaluable patients with measurable disease.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.7.2-2"></a>

##### Follow-up calculation and pharmacokinetic sampling

> “Follow-up was calculated from first dose date to data cutoff date regardless of disease progression status.”
> “Rich pharmacokinetic samples collected at cycle 2 day 15.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.7.2-3"></a>

##### Clinical benefit rate definition

> “CBR is the proportion of patients who remained on treatment through at least 24 weeks with a confirmed complete response or partial response, or stable disease.”

Source: [Borges et al. (2024b)](https://ir.olema.com/static-files/dfb83ebb-df49-47a3-a585-ec416cc48954)

<a id="topic-3.1.3.7.2-4"></a>

##### Central ESR1 mutation testing

> “ESR1 mutations in ctDNA at baseline were determined centrally using SafeSEQ Breast Cancer Panel (Sysmex Inostics, Baltimore, MD). Three samples were not evaluable.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="heading-3.1.3.8"></a>

### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

#### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

##### Ribociclib group: treatment status, July 2025 data cutoff

> “42% (30/72) patients remain on treatment; efficacy maturing.”
> “The longest duration of treatment in the 120 mg cohort is 103 weeks and ongoing.”
> “The most common reason for treatment discontinuation was disease progression.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.8.1-2"></a>

##### Ribociclib group: discontinuations due to adverse events

> “Three patients discontinued both treatments due to a TEAE (depression Gr 3, n=1; neutropenia Gr 4, n=1; vomiting and febrile neutropenia both Gr 3, n=1) and 3 patients discontinued ribociclib only (neutropenia Gr 4, n=2; fatigue Gr 3, n=1).”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="heading-3.1.3.8.2"></a>

#### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

##### Ribociclib group: baseline demographics and disease characteristics, July 2025 data cutoff

| Characteristic | Palazestrant 90 mg (n=16) | Palazestrant 120 mg (n=56) | Total (N=72) |
| --- | --- | --- | --- |
| Median age, years (range) | “60 (25-76)” | “61 (28-85)” | “61 (25-85)” |
| Female sex, n (%) | “16 (100%)” | “56 (100%)” | “72 (100%)” |
| Premenopausal, n (%) | “4 (25%)” | “8 (14%)” | “12 (17%)” |
| ECOG performance status 0, n (%) | “10 (63%)” | “34 (61%)” | “44 (61%)” |
| ECOG performance status 1, n (%) | “6 (38%)” | “22 (39%)” | “28 (39%)” |
| Measurable disease at baseline, n (%) | “12 (75%)” | “37 (66%)” | “49 (68%)” |
| Visceral disease, n (%) | “6 (38%)” | “33 (59%)” | “39 (54%)” |
| No prior line of therapy in the advanced setting, n (%) | “10 (63%)” | “14 (25%)” | “24 (33%)” |
| One prior line of therapy in the advanced setting, n (%) | “5 (31%)” | “26 (46%)” | “31 (43%)” |
| Two prior lines of therapy in the advanced setting, n (%) | “1 (6.3%)” | “12 (21%)” | “13 (18%)” |
| Three prior lines of therapy in the advanced setting, n (%) | “0” | “4 (7%)” | “4 (6%)” |
| Prior CDK4/6 inhibitor in the advanced setting, n (%) | “5 (31%)” | “40 (71%)” | “45 (63%)” |
| Prior aromatase inhibitor in the advanced setting, n (%) | “5 (31%)” | “27 (48%)” | “32 (44%)” |
| Prior fulvestrant in the advanced setting, n (%) | “1 (6%)” | “22 (39%)” | “23 (32%)” |
| Prior chemotherapy in the advanced setting, n (%) | “1 (6.3%)” | “10 (18%)” | “11 (15%)” |
| ESR1 mutation at baseline | “1/15 (7%)” | “14/54 (26%)” | “15/69 (22%)” |

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.8.2-2"></a>

##### Ribociclib group: prior CDK4/6 inhibitor exposure and ESR1 mutation status

> “45 (63%) patients (40 patients at 120 mg; 5 patients at 90 mg) received prior CDK4/6i with endocrine therapy for advanced disease.”
> “36 (50%) received 1 prior CDK4/6i (palbociclib, n=23; abemaciclib, n=8; ribociclib, n=5).”
> “At baseline, 22% (15/69) of all patients had tumors with ESR1 mutations; 33% (15/45) of patients with one prior line of therapy in the advanced setting (2L/3L+) had tumors with ESR1 mutations.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="heading-3.1.3.8.3"></a>

#### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

##### Ribociclib group: progression-free survival in the 120 mg cohort, including participants with prior CDK4/6 inhibitor treatment

> “For patients in the palazestrant 120 mg dose cohort, median PFS was 15.5 mos for all patients, 12.2 mos with prior CDK4/6i, 9.2 mos for ESR1-wt with prior CDK4/6i, and 13.8 mos for ESR1-mut with prior CDK4/6i-treated ABC.”
> “Among all patients, median follow-up was 19.1 mos, 19.8 mos in patients with prior CDK4/6i, 20 mos in patients with ESR1-wt disease with prior CDK4/6i, and 18.0 mos for patients with ESR1-mut disease with prior CDK4/6i treatment.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.8.3-2"></a>

##### Ribociclib group: maturity of progression-free survival in the 120 mg cohort

> “In the 120 mg palazestrant dose cohort, with a median follow-up of more than 19 months, median PFS are mature.”

Source: [Olema Oncology ESMO 2025 ribociclib results announcement (2025)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-new-data-phase-1b2-trial-palazestrant)

<a id="topic-3.1.3.8.3-3"></a>

##### Ribociclib group: progression-free survival in the 90 mg cohort

> “In the 90 mg palazestrant dose cohort, the median follow-up was 10.8 months. The median PFS was not reached.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.8.3-4"></a>

##### Ribociclib group: objective response rate, July 2025 data cutoff

| Population | Objective response rate (n/n) |
| --- | --- |
| 90 mg cohort (n=12) | “42% (5/12)” |
| 120 mg cohort (n=32) | “31% (10/32)” |
| Prior CDK4/6i, 120 mg cohort (n=23) | “26% (6/23)” |
| All (n=44) | “34% (15/44)” |

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.8.3-5"></a>

##### Ribociclib group: responses after prior CDK4/6 inhibitor treatment

> “26% (6/23) ORR among patients with prior CDK4/6i, including 6 confirmed partial responses (cPRs) in the 120 mg cohort.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.8.3-6"></a>

##### Ribociclib group: 6-month progression-free survival and clinical benefit rate, September 2024 data cutoff

> “With a median follow-up of 10 months, median PFS was not reached.”
> “6-month PFS rate was 72% in all patients, 67% with prior CDK4/6i, 70% with ESR1-wt and 81% with ESR1-mut mBC.”
> “CBR was 76% in all patients, 71% with prior CDK4/6i, 74% with ESR1-wt and 81% with ESR1-mut mBC.”

Source: [Borges et al. (2024b)](https://ir.olema.com/static-files/dfb83ebb-df49-47a3-a585-ec416cc48954)

<a id="topic-3.1.3.8.3-7"></a>

##### Ribociclib group: clinical benefit rate after prior CDK4/6 inhibitor treatment, November 2024 data cutoff

> “In patients with prior CDK4/6i treatment, the CBR was 71% (25/35), 81% (13/16) in patients with ESR1 mutations, and 65% (11/17) in ESR1 wild-type patients.”

Source: [Olema Oncology SABCS 2024 announcement (2024)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-presents-updated-clinical-results-palazestrant)

<a id="topic-3.1.3.8.3-8"></a>

##### Ribociclib group: pharmacokinetic interaction results

> “Palazestrant had no clinically meaningful effect on ribociclib 600 mg steady-state exposure when compared with published concentrations for single-agent ribociclib.”
> “Ribociclib had no clinically meaningful effect on palazestrant exposure”
> “Steady-state plasma concentrations at both 90 mg and 120 mg doses exceeded the predicted efficacious threshold”
> “There was no clinically significant difference in exposure between 90 mg and 120 mg doses.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.8.3-9"></a>

##### Ribociclib group: steady-state ribociclib 600 mg exposure, October 2023 data cutoff

| Parameter | Ribociclib single agent | Ribociclib in combination with palazestrant |
| --- | --- | --- |
| AUC0-24 ([h*ng/mL]/mg), GeoMean (GeoCV); N | “23,800 (66%); 54” | “25,400 (78%); 8” |
| Cmax (ng/mL/mg), GeoMean (GeoCV); N | “1,820 (62%); 57” | “1,860 (66%); 8” |
| Tmax (h), Median (min–max); N | “2.4 (0.68–7.8); 57” | “4.0 (1.0–6.0); 8” |

Source: [Borges et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-003_12-5-23.pdf)

<a id="topic-3.1.3.8.3-10"></a>

##### Ribociclib group: CYP3A4 interaction mechanism

> “Ribociclib is metabolized mainly by CYP3A4. Palazestrant is not a CYP3A4 inhibitor or inducer.”
> “Ribociclib is a strong inhibitor of CYP3A4. While palazestrant is metabolized by CYP3A4, it is not sensitive to CYP3A4 inhibition.”

Source: [Borges et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-003_12-5-23.pdf)

<a id="topic-3.1.3.8.3-11"></a>

##### Everolimus and atirmociclib groups: first data scheduled for December 2026

> “Title: Palazestrant (OP-1250) in combination with everolimus, a phase 1b/2 study, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) advanced or metastatic breast cancer”
> “Title: Palazestrant (OP-1250) in combination with atirmociclib, a phase 1b study, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) advanced or metastatic breast cancer”

Source: [Olema Oncology SABCS 2026 presentations announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-present-combination-data-palazestrant-and-op-3136)

<a id="topic-3.1.3.8.3-12"></a>

##### Atirmociclib group: data timing

> “The Phase 1b/2 study investigating palazestrant in combination with atirmociclib has completed enrollment and we expect to present initial data at the San Antonio Breast Cancer Symposium (SABCS) in December 2026.”

Source: [Olema Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526454421/olma-20260930.htm)

Additional sources: [Lin et al. (2025a)](https://www.annalsofoncology.org/article/S0923-7534(25)01845-9/fulltext)

<a id="heading-3.1.3.8.4"></a>

#### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

#### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

##### Ribociclib group: dose-limiting toxicities and overall severity

> “No dose-limiting toxicities were observed during the dose-escalation phase, and the maximum tolerated dose was not reached.”
> “The majority of related TEAEs were grade 1 and 2.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.8.5-2"></a>

##### Ribociclib group: related treatment-emergent adverse events in at least 25% of participants, n (%)

| Event | 120 mg (n=56), all grades | 120 mg, grade 3 | 120 mg, grade 4 | 90 mg (n=16), all grades | 90 mg, grade 3 | 90 mg, grade 4 |
| --- | --- | --- | --- | --- | --- | --- |
| Neutropenia (combined term) | “47 (84%)” | “28 (50%)” | “5 (9%)” | “13 (81%)” | “9 (56%)” | “2 (16%)” |
| Nausea | “41 (73%)” | “2 (4%)” | “0” | “11 (69%)” | “1 (6%)” | “0” |
| Fatigue | “30 (54%)” | “3 (5%)” | “0” | “9 (50%)” | “0” | “0” |
| White blood cell decrease | “24 (43%)” | “9 (16%)” | “1 (2%)” | “6 (38%)” | “4 (25%)” | “0” |
| Diarrhea | “24 (43%)” | “2 (4%)” | “0” | “4 (25%)” | “0” | “0” |
| Anemia | “22 (39%)” | “2 (4%)” | “0” | “5 (31%)” | “0” | “0” |
| Vomiting | “21 (38%)” | “1 (2%)” | “0” | “4 (25%)” | “0” | “0” |
| Electrocardiogram QT prolonged | “16 (29%)” | “4 (5%)” | “0” | “4 (25%)” | “1 (6%)” | “0” |
| Lymphocyte decrease | “16 (29%)” | “3 (5%)” | “1 (2%)” | “3 (19%)” | “0” | “0” |
| AST increased | “15 (27%)” | “2 (4%)” | “0” | “3 (19%)” | “0” | “0” |
| Constipation | “15 (27%)” | “0” | “0” | “3 (19%)” | “0” | “0” |

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.8.5-3"></a>

##### Ribociclib group: dose reductions and grade 5 events

> “2 patients had a dose reduction of palazestrant only; 1 due to nausea and 1 due to neutropenia”
> “8 patients had a dose reduction of both treatments; 23 patients had a dose reduction of ribociclib. The most common cause for dose reduction was neutropenia.”
> “Two patients experienced Gr 5 AEs: organ failure, and depressed level of consciousness; none of which were related to palazestrant.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.8.5-4"></a>

##### Ribociclib group: reasons for ribociclib dose reduction, March 2024 data cutoff

> “10 patients had dose reduction of ribociclib only. Reasons for dose reduction were QTcF prolongation (n=4; Grade 3, n=2; Grade 2, n=1; Grade 1, n=1), neutropenia (n=4; Grade 3, n=3; Grade 2, n=1) or fatigue (n=2; Grade 2).”

Source: [Borges et al. (2024a)](https://olema.com/wp-content/uploads/2024/05/Olema_Final_ESMO-Breast-2024_OP-1250-003_5-15-24.pdf)

<a id="topic-3.1.3.8.5-5"></a>

##### Ribociclib group: QTcF in the dose-escalation analysis

> “No QTcF values of >500 ms were observed at any time point.”

Source: [Borges et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-003_12-5-23.pdf)

<a id="heading-3.1.3.9"></a>

### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

#### Summary

OP-1250-003 is an open-label phase 1b, 2-part study in 4 treatment groups, and the 2025 presentation cautions that its comparison aggregates results across independent studies and carries the risks inherent in cross-trial comparisons. The ribociclib group population differs from this indication: 24 of 72 participants (33%) had no prior line of therapy in the advanced setting, and 45 (63%) had received a prior CDK4/6 inhibitor. Cohorts include 16 participants at palazestrant 90 mg and 56 at 120 mg, and response rates are based on 12 and 32 response-evaluable participants, respectively. The presentation describes efficacy as “maturing”: 30 of 72 participants (42%) remained on treatment at the July 8, 2025 cutoff, and median PFS in the 90 mg cohort was not reached at a median follow-up of 10.8 months. Responses were assessed by the investigator, and the analysis presented 72 of 78 enrolled participants. Interim results were reported at successive cutoffs (March 13, 2024; September 25, 2024; and July 8, 2025) with different analysis populations.

Source: [ClinicalTrials.gov NCT05508906](https://clinicaltrials.gov/study/NCT05508906); [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97); [Borges et al. (2024a)](https://olema.com/wp-content/uploads/2024/05/Olema_Final_ESMO-Breast-2024_OP-1250-003_5-15-24.pdf); [Borges et al. (2024b)](https://ir.olema.com/static-files/dfb83ebb-df49-47a3-a585-ec416cc48954)

<a id="topic-3.1.3.9-2"></a>

#### Cross-trial comparison with MONALEESA-2

> “This analysis is the aggregation of results across independent studies. There are risks inherent in conducting cross-trial comparisons and results should be interpreted with caution.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.9-3"></a>

#### Open-label design without a comparator group

> “This is a Phase 1b open-label, 2-part study in 4 treatment groups.”

Source: [ClinicalTrials.gov NCT05508906](https://clinicaltrials.gov/study/NCT05508906)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
